Stockreport

Spero Announces Positive Interim Phase 1 SAD/MAD Results for SPR994

Spero Therapeutics, Inc.  (SPRO) 
Last spero therapeutics, inc. earnings: 3/16 08:45 am Check Earnings Report
US:NASDAQ Investor Relations: investors.sperotherapeutics.com/overview
PDF Clinical data demonstrate SPR994 to be well tolerated at single and multiple ascending dosesData support selection of SPR994 300 mg TID dose for use in a pivotal Phase 3 [Read more]